Panelists discuss how bronchiectasis is more common than previously thought, with growing awareness, research, and specialized centers improving diagnosis and treatment options, though challenges remain in standardizing care and securing insurance coverage for therapies.
Clinical Brief: Unmet Needs in Bronchiectasis Management
Main Discussion Topics
Key Points for Physicians
Notable Insights
The panel emphasized that bronchiectasis is not a rare disease, as previously thought, but is rather common and significantly impacts quality of life, making investment in better detection and management crucial.
Clinical Significance
Despite recent advances, substantial unmet needs remain in bronchiectasis management, creating opportunities for research and clinical practice improvement to reduce the significant burden of this disease.
Zilucoplan Shows Rapid, Durable, Steroid-Sparing Benefits in gMG
June 12th 2025Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).
Read More
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More